Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes : the randomised, head-to-head CONCLUDE trial

Philis-Tsimikas, A., Klonoff, D.C., Khunti, K. et al. (7 more authors) (2020) Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes : the randomised, head-to-head CONCLUDE trial. Diabetologia, 63 (4). pp. 698-710. ISSN 0012-186X

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2020 The Authors. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made (http://creativecommons.org/licenses/by/4.0/).
Keywords: Clinical science; Hypoglycaemia; Insulin degludec; Insulin glargine; Insulin therapy
Dates:
  • Accepted: 4 December 2019
  • Published (online): 27 January 2020
  • Published: April 2020
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield)
Depositing User: Symplectic Sheffield
Date Deposited: 09 Mar 2020 14:46
Last Modified: 09 Mar 2020 14:46
Status: Published
Publisher: Springer Nature
Refereed: Yes
Identification Number: https://doi.org/10.1007/s00125-019-05080-9
Related URLs:

Share / Export

Statistics